RaQualia Pharma (TSE:4579) Cash per Share: 円180.41 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
62 GF Score
Price 円542.00
GF Value 円839.15
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is RaQualia Pharma Cash per Share?

RaQualia Pharma TSE:4579 -1.99% 62 Cash per Share is 円180.41 as of Jun. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 62/100 and a GF Value™ of 円839.15 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). RaQualia Pharma's Cash per Share for the quarter that ended in Jun. 2026 was 円180.41.

RaQualia Pharma  (TSE:4579) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

RaQualia Pharma Cash per Share Related Terms

RaQualia Pharma Cash per Share Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Cash per Share Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 126.90 187.16 174.11 153.03 132.65

RaQualia Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 148.12 144.88 132.65 172.75 180.41
TSE:4579
62GF Score
RaQualia Pharma Inc TSE:4579
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

RaQualia Pharma's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=3244.274/24
=132.65

RaQualia Pharma's Cash per Share for the quarter that ended in Jun. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=4696.315/26
=180.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of 円180.41 mean?
RaQualia Pharma (TSE:4579) has a Cash per Share of 円180.41 as of Jun. 2026. Cash per share is the per-share value of a company's available cash. View historical data for RaQualia Pharma and its competitors.
Is RaQualia Pharma's Cash per Share too high?
RaQualia Pharma's current Cash per Share is 円180.41. Overall, RaQualia Pharma has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Cash per Share compare to VRTX and REGN?
RaQualia Pharma's Cash per Share of 円180.41 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for RaQualia Pharma and its competitors. RaQualia Pharma's current Cash per Share is 円180.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円839.15, compared to a current price of 円542.00 — trading 35.4% below its estimated fair value. The current Cash per Share is 円180.41. RaQualia Pharma's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Cash per Share is 円180.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued. The current stock price of 円542.00 is trading 35.4% below its estimated GF Value™ of 円839.15. GuruFocus considers RaQualia Pharma to be Significantly Undervalued.

Key valuation signals for TSE:4579:

  • Cash per Share: 円180.41
  • GF Value™: 円839.15 vs. price of 円542.00 (35.4% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
62GF Score

Get the complete analysis for TSE:4579

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円542.00
Price
円839.15
GF Value